TM2D1 (TM2 domain containing 1) is a protein implicated in amyloid-beta-induced apoptotic signaling. Based on functional studies, TM2D1 participates in apoptotic pathways potentially through interaction with amyloid-beta and related proteins 1. The protein contains conserved structural domains shared with related family members involved in G protein signaling modulation, though direct G protein coupling mechanisms remain unclear 2. In colorectal cancer models, TM2D1 functions as a key regulatory target of anesthetic agents. Sevoflurane and propofol co-treatment suppressed colorectal cancer cell proliferation, invasion, and migration while promoting apoptosis and ferroptosis—effects that were reversed by TM2D1 overexpression, establishing TM2D1 as a critical mediator of anesthetic-induced anti-tumor activity 3. Beyond oncology, TM2D1 was identified as one of six hub genes with high diagnostic significance for patients with co-occurring ankylosing spondylitis and sarcopenia, suggesting broader roles in inflammatory and metabolic disease pathways 4. Clinically, TM2D1 represents a potential therapeutic target for colorectal cancer treatment and may have diagnostic utility in musculoskeletal disease management. Its involvement in amyloid-beta signaling also suggests relevance to Alzheimer's disease pathophysiology, consistent with the broader disease associations of related TM2 domain proteins 5.